Please assess the completion status of the following clinical trial:

Trial Title: A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adults aged ≥40 years~* Patients with stable COPD according to GOLD strategy (GOLD 2011).~* Patients with airflow limitation indicated by a post-bronchodilator FEV1 ≥ 30% and \<80% of the predicted normal, and a post-bronchodilator FEV1/FVC \< 0.70.~* Current or ex-smokers who have a smoking history of at least 10 pack years.~* Patients with an mMRC ≥ grade 2~Exclusion Criteria:~* History of long QT syndrome or prolonged QTc~* Patients who have had a COPD exacerbation that required treatment with antibiotics and/or systemic corticosteroids and/or hospitalization in the 6 weeks prior to Visit 1.~* Patients with Type I or uncontrolled Type II diabetes~* Patients with a history of asthma or have concomitant pulmonary disease~* Patients with paroxysmal (e.g. intermittent) atrial fibrillation. Only patients with persistent atrial fibrillation and controlled with a rate control strategy for at least six months could be eligible~* Patients who have clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities which could interfere with the assessment of safety~* Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QVA149 dose 1 (Type: EXPERIMENTAL): QVA149 27.5/12.5 μg capsules
- QVA149 dose 2 (Type: EXPERIMENTAL): QVA149 27.5/25 μg capsules
- QAB149 (Type: ACTIVE_COMPARATOR): QAB149 75 μg capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).